Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide
Operational Update on May 9
BUFFALO, N.Y., April 30, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) today announced that on May 9, 2013 before the market opens, it
will report its first quarter 2013 financial results for the period ended
March 31, 2013, and will host a conference call at 10:00 a.m. ET.
Interested parties may participate by dialing 877-407-8031 (US) or
201-689-8031 (International), approximately five to ten minutes before the
call start time. A live webcast of the conference call will be available on
the investor page of the Cleveland BioLabs web site at www.cbiolabs.com.
A replay of the call will be available starting on May 9, 2013, at 1:00 p.m.
ET through May 23, 2013, at 11:59 p.m. ET.Interested parties may access the
replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and
entering conference ID number 413582.An archived webcast of the conference
call will be available on the investor page of the Cleveland BioLabs web site
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at http://www.cbiolabs.com.
Rachel Levine, Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.